토라세미드

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• Known hypersensitivity to torsemide or other sulfonylureas
• Anuric patients

이상반응

• Fluid and electrolyte abnormalities (hyponatremia, hypocalcemia, hypokalemia, hypomagnesemia)
• Prerenal azotemia (secondary to dehydration)
• Gastrointestinal disturbances
• Hematologic effects (anemia, leukopenia)
• Weakness
• Restlessness
• Ototoxicity (rare, associated with rapid IV administration)

약물 상호작용

• ACE Inhibitors (e.g., enalapril, benazepril) · Increased risks for hypotension, particularly in patients who are volume or sodium depleted secondary to diuretics
• Aminoglycosides (gentamicin, amikacin, etc.) · May increase the ototoxic or nephrotoxic risks of aminoglycosides
• Amphotericin B · May increase the risk for nephrotoxicity development
• Digoxin · Can increase the area under the curve of torsemide by 50%; torsemide-induced hypokalemia may increase the potential for digoxin toxicity
• Lithium · Torsemide may reduce lithium clearance
• NSAIDs · Some NSAIDs may reduce the natriuretic effects of torsemide
• Probenecid · Can reduce the diuretic efficacy of torsemide
• Salicylates · Torsemide can reduce the excretion of salicylates

모니터링

• Serum electrolytes (especially potassium, sodium, calcium, magnesium)
• BUN and creatinine
• Blood glucose (if diabetic)
• Hydration status
• Blood pressure (if indicated)
• Clinical signs of edema and patient weight

과용량

In dogs, the oral LD50 is >2 grams/kg. **Fluid and electrolyte imbalance** is the most likely risk associated with an overdose. * Consider gut emptying protocols for very large or quantity unknown ingestions. * Acute overdoses should generally be managed by observation with fluid, electrolyte, and acid-base monitoring. * Supportive treatment should be initiated if required.